ScholarWorks@Korea University College of Medicine: Park, Kyong Hwa

Detailed Information

Park, Kyong Hwa (박경화)

Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area: 유방암 치료 내성 기전 및 정밀의료, 종양백신, 바이오마커, Resistance mechanism and precision medicine in breast cancer, Cancer vaccine, Biomarkers

Tel +8229206841
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast cancer:14||Breast neoplasms:10||Chemotherapy:9||Metastatic breast cancer:7||lung cancer:6||chemotherapy:6||Gemcitabine:5||Lung cancer:4||Metaanalysis:4||HER2:4||Neutropenia:4||Korea:4||RASSF1A:4||Adjuvant chemotherapy:4||Docetaxel:4||Prognosis:3||Colorectal neoplasms:3||docetaxel:3||Anthracycline:3||epirubicin:3||Vinorelbine:3||cisplatin:3||Clinical trial:3||breast cancer:3||Highthroughput nucleotide sequencing:3||Trastuzumab:3||prognostic model:2||gastric cancer:2||Breast cancer risk:2||Biomarkers:2||paclitaxel:2||Oxaliplatin:2||Rituximab chemotherapy:2||Nonsmallcell lung carcinoma:2||Survival:2||Breast:2||PIK3CA:2||TAC chemotherapy:2||overall survival:2||Pegylated GCSF:2||breast neoplasm:2||Sarcoma:2||SNP:2||telomere length:2||KRAS:2||leucovorin:2||liquid biopsy:2||Genomics:2||Everolimus:2||UFT:2||EGFR mutation:2||Lung adenocarcinoma:2||cyclin B1:2||Haplotypes:2||Cauda equina syndrome:2||Febrile neutropenia:2||cellfree DNA:2||prognosis:2||Primary adrenal lymphoma:2||Cisplatin:1||Cisplatin failure:1||Cisplatinunfit:1||Clear cell adenocarcinoma:1||Clinical diagnosis:1||Clonality analysis:1||Clostridium difficile:1||Clustering:1||Coarse Calcification:1||Colonic neoplasms:1||Combination chemotherapy:1||Concomitant chemoradiation:1||Congestive heart failure:1||Continuity of patient care:1||DHP107:1||DNA detection:1||DNA polymorphism:1||DNA sensor:1||Dalotuzumab:1||Diagnosis:1||Diffuse large B cell lymphoma:1||Diffusionweighted imaging:1||Dovitinib:1||Doxorubicin:1||Drosophila melanogaster:1||Drug therapy:1||Ductal:1||E2:1||EGFR:1||ER (+) HER2 (+):1||ERBB3 gene:1||ERCC1:1||ERK phosphorylation:1||Elderly:1||Endoflife care:1||Endocardium:1||Epidermal growth factor receptor mutation:1||Epirubicin:1||ErbB2:1||Eribulin:1||Esophageal squamous cell carcinoma:1||Exemestane:1||Exosomal miRNA:1||FDG PET:1||FDG PET/CT:1||FOLFIRI:1||FOLFOX:1||FSH:1||Flow cytometry:1||Foxp3(+) Treg:1||Gastric cancer:1||Gemcitabine and carboplatin:1||Gene amplification:1||Genomic landscape:1||Germline mutation:1||Gold nanoparticles (AuNPs):1||Granulysin:1||HER2 positive:1||HER2Positive breast cancer:1||HER2negative:1||HSP90:1||HUMARA assay:1||Hairpin DNA:1||Head and neck neoplasms:1||Health Partner Program:1||Health coaching:1||Health partnership:1||Hematologic malignancy:1||Hepatocellular neoplasm:1||IGFIR:1||IGF1R:1||IGFBP3:1||Immune checkpoint inhibitors:1||Immunohistochemistry:1||Immunology:1||Irinotecan:1||Janus kinase 3:1||KRAS mutation:1||Klenow fragment:1||Korean:1||Korean population:1||Koreans:1||LNA:1||LOD:1||Labelfree detection:1||Lapatinib:1||Lapatinib resistance:1||Letrozole:1||Leucovorin:1||Liquid biopsy:1||Long coronary lesion:1||Longacting granulocytecolony stimulating factor:1||Luminal breast cancer:1||Lung neoplasms:1||Lymphatic Metastasis:1||Lymphoma:1||MVAC protocol:1||MDAMB231:1||Magnetic resonance imaging:1||Malignancy:1||Mammalian target of rapamycin inhibitor:1||Mammography:1||Massage:1||Mendelian randomization:1||Menstruation:1||Metabolic tumor volume:1||Metastatic burden:1||Metastatic cancer:1||Minimized blood transfusion:1||Mistletoe:1||Molecular:1||Molecular subtypes:1||Multifocal tumor:1||Multiple tumor:1||Myelodysplastic syndrome:1||Myeloid derived suppressor cells:1||NSCLC:1||Nasopharyngeal carcinoma:1||Neoadjuvant chemotherapy:1||Neoplasm metastasis:1||Nivolumab:1||Nomogram:1||Nonsmallcell lung cancer:1||Obesity:1||Offlabel use:1||Oncogenes:1||Oncology aesthetic:1||Ovarian cancer:1||Ovarian epithelial carcinoma:1||Ovarian function:1||Ovarian neoplasms:1||Overall survival:1||PAK2:1||PCR:1||PET computed tomographic:1||PIM:1||PIM1:1||Pain control:1||Palliative care:1||Pancreas neoplasm:1||Pancreatic adenocarcinoma:1||Pathology:1||Pathway analysis:1||Patient blood management:1||Pemetrexed:1||Peptide nucleic acid:1||Peptide vaccine:1||Percutaneous coronary intervention:1||Peroxisome proliferating response elememt:1||Phosphoproteomics:1||Physician orders for lifesustaining treatment:1||Plasmonic biosensors:1||Platinum resistant:1||Point mutation:1||Polymorphism:1||Positive thinking:1||Postmenopause:1||Precision medicine:1||Principal component analysis:1||Prognostic factors:1||Prognostic marker:1||Prognostic model:1||Progressionfree survival:1||Prostate cancer:1||Protein expression:1||Rab25:1||Randomized phase II trial:1||Rayleigh scattering:1||Receptor, epidermal growth factor:1||Receptors, estrogen:1||Regular exercise:1||Renal cell carcinoma:1||Reninangiotensin system:1||Retrospective analysis:1||Retrospective study:1||Ribonuclease:1||Ridaforolimus:1||Rosuvastatin:1||Salvage therapy:1||Salvage treatment:1||Second primary cancer:1||Secondline:1||Secondline chemotherapy:1||Selectivity:1||Sensitive:1||Serum and tumor samples:1||Single Nucleotide Polymorphism:1||Single nucleotide polymorphism:1||Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a korean population:1||Solid cancer:1||Spontaneous tumor:1||Spot stenting:1||Squamous cell carcinoma of the head and neck:1||Stage:1||Strain:1||Surfaceenhanced Raman scattering (SERS):1||T helper 1:1||Tcell nonHodgkin lymphoma:1||TGFbeta 1:1||Tamoxifen:1||Targetable gene alteration:1||Taxane acute pain syndrome:1||Taxanes:1||Th1:1||Th2:1||Therapy:1||Total lesion glycolysis:1||Transcatheter arterial chemoembolization:1||Trastuzumab biosimilar:1||Treatment outcome:1||Tuberculosis:1||Tuberous sclerosis complex:1||Tumor mutation burden:1||Twin births:1||Tyrosine kinase inhibitors:1||UFTE:1||UVvis absorbance:1||Ultrasonography:1||University students:1||Urine:1||Urothelial cancer:1||Urothelial carcinoma:1||Urothelial cell carcinoma:1||VEGF:1||Varicella zoster virus:1||Vascular endothelial growth factor:1||Weekly docetaxel:1||YKL40:1||advanced non small cell lung cancer:1||aggressive fibromatosis:1||alphaamylase:1||anemia:1||arthritis:1||association study:1||azaMichael addition click reaction:1||bevacizumab:1||biliary tract carcinoma:1||blood:1||cancer:1||cancer chemotherapy, nonmyeloablative:1||cancer diagnosis:1||cancer patients:1||capecitabine:1||carboplatin:1||carpal bones:1||castrationresistant prostate cancer:1||cellfree DNA concentration:1||cfDNA:1||characteristic:1||cholangiocarcinoma:1||colorectal cancer:1||coronavirus disease 2019:1||ctDNA:1||cyclin A:1||cyclindependent kinase 5 (CDK5):1||density:1||diffusion magnetic resonance imaging:1||early breast cancer:1||elderly:1||elderly patients:1||encoded hydrogel microparticle:1||endocrine therapy:1||endocytosis:1||epitope mapping:1||esophageal cancer:1||estrogen receptorpositive:1||exosome:1||extracellular vesicle:1||firstline:1||gefitinib:1||genetic risk score:1||genetics:1||gold nanoparticles:1||haplotype:1||health coaches:1||hepatocellular carcinoma:1||hot spot mutants:1||hypoxia:1||iNOS:1||immunity:1||immunization:1||immunotherapy:1||incidence:1||isolation:1||lapatinib resistance:1||localized surface plasmon resonance (LSPR):1||longterm cancer survivors:1||lymphocytes, tumorinfiltrating:1||mTOR:1||mTOR inhibitor:1||metastatic breast cancer:1||methotrexate:1||methylation:1||microRNA:1||missense mutation:1||mitomycin:1||molecular targeted therapy:1||more than thirdline:1||multiplex polymerase chain reaction:1||mutations:1||neoadjuvant:1||neoadjuvant chemotherapy:1||neutropenia:1||nonsmallcell lung cancer:1||nonsmallcell lung carcinoma:1||oral UFT:1||oral paclitaxel:1||ovarian function suppression:1||p53 protein:1||p53 protein mutation:1||pathologic complete response:1||pathological complete response:1||perception:1||perfusion:1||plasmonic headflocked gold nanopillar:1||platelet count:1||polymer:1||probeset modification:1||prognosis factor:1||prognostic value:1||rayleigh scattering:1||refractory colon cancer:1||response:1||safety:1||secondline chemotherapy:1||sequencing:1||serum and tumor samples:1||single nucleotide polymorphism (SNP):1||singlenucleotide polymorphism:1||stomach:1||stomach neoplasms:1||stop flow lithography:1||streptavidin:1||surfaceenhanced Raman scattering (SERS):1||targeted therapy:1||transcriptional activity:1||trastuzumab:1||trastuzumabpkrb:1||triple negative breast cancer | lymph node negative | p53 | Ki67 | young age:1||triplenegative breast cancer:1||tumor microenvironment:1||tumorderive extracellular vesicles:1||uPAR:1||uracil plus tegafur (UFT):1||urine:1||urothelial carcinoma:1||vaccine:1||vascular endothelial growth factor:1||vinblastine:1||& nbsp:1||vincristine:1||276 C/T polymorphism:1||509 C/T polymorphism:1||3D hierarchical nanostructure:1||5FU:1||5Fluorouracil:1||936 C/T polymorphism:1||ACEI/ARB:1||Acute myeloid leukaemia:1||Adoptive T cell therapy:1||Advance directives:1||Advanced breast cancer:1||Advanced colorectal cancer:1||Advanced soft tissue sarcoma:1||Aged:1||Albumin:1||Allelespecific amplification:1||Anthracyclines:1||AntiEGFR:1||Apoptosis:1||Aromatherapy:1||Asians:1||AuNPs:1||Axilla:1||Axillary lymph node metastasis:1||BRCA:1||BRCA1 gene:1||Balanced diet:1||Bevacizumab:1||Bicarbonate:1||Biliary tract cancer:1||Blood:1||Bone morphogenetic protein2:1||Breast Cancer:1||Breast Neoplasms:1||Breast cancer antigen:1||Breast neoplasm:1||Creactive protein:1||CD4 T cell:1||CD4positive Tlymphocytes:1||CD8(+) T cell:1||CHA:1||COVID19:1||CXCR4:1||Cancer perception:1||Cancer stem cell:1||Cancer vaccine:1||Cancerrelated anemia:1||Candesartan:1||Capecitabine:1||Carboplatin:1||Carcinoma:1||Cardiomyopathy:1||Cardiotoxicity:1||Castrationresistant prostatic neoplasm:1||Caveolin 1:1||Cellfree nucleic acids quantification:1||Chemotherapy, second line:1||Chest xray:1||

STATISTICS: Total View :12,810,345; Today View :7,127

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE